CCR5-001

CCR5-001 is a novel Drug Fc-Conjugate (DFC) designed to target the chemokine receptor CCR5. It acts by binding potently to CCR5, outcompeting the natural ligand CCL5, and functionally inhibiting CCR5 signaling as demonstrated in cell-based β-arrestin assays. This mechanism disrupts the CCR5/CCL5 axis involved in cancer pathology both by preventing tumor infiltration of immunosuppressive immune cells (cancer-extrinsic effect) and by blocking autocrine CCR5 signaling that promotes metastasis (cancer-intrinsic effect). Developed primarily for solid cancers such as colorectal cancer, it has shown robust efficacy as a monotherapy in syngeneic mouse models of colorectal cancer with significant tumor growth inhibition. The drug represents an innovative approach using DFC technology to target immune-suppressive pathways in tumors driven by the CCR5/CCL5 axis.

Other names

CCR5 Drug-Fc ConjugateCCR-5 Drug-Fc ConjugateCCR 5 Drug-Fc ConjugateCCR5-DFCCCR-5-DFCCCR 5-DFCCCR5-targeting DFCCCR-5-targeting DFCCCR 5-targeting DFC